Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
As the leader womenâs health, we deliver life-changing and life-saving diagnosti...
As the leader womenâs health, we deliver life...
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused o...
BioXcel Therapeutics, Inc. is a clinical stage ...
Ocugen is a clinical stage biopharmaceutical company focused on discovering, devel...
Ocugen is a clinical stage biopharmaceutical co...
Eton Pharmaceuticals, Inc. is a Deer Park, IL-based biopharmaceutical company focu...
Eton Pharmaceuticals, Inc. is a Deer Park, IL-b...
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and ...
Catalyst Pharmaceuticals is a biopharmaceutical...
Aytu is committed to better health for men and women here at home and worldwide. W...
Aytu is committed to better health for men and ...
Dicerna is a biopharmaceutical company focused on the discovery and development of...
Dicerna is a biopharmaceutical company focused ...
Join the National Investor Network and get the latest information with your interests in mind.